|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues from sales | |||||
| Cost of sales (Note 15) | |||||
| Gross profit | |||||
| Research and development expenses (Note 17) | |||||
| Selling and marketing expenses (Note 17) | |||||
| General and administrative expenses, exclusive of depreciation and amortization (Note 18) | |||||
| Change in fair value of contingent consideration | |||||
| Depreciation and amortization (Note 4) | |||||
| Operating loss | |||||
| Financing income, net (Note 16) | |||||
| Financing income (expense), net (Note 19) | |||||
| Other income (Note 13(14)) | |||||
| Financing expense, net (Note 19) | |||||
| Other income (Note 15(7)) | |||||
| Changes in fair value of investments measured under the fair value option (Notes 6, 7) | |||||
| Net loss before tax | |||||
| Income taxes | |||||
| Net loss from continuing operation | |||||
| Net loss from discontinued operations (Note 11) | |||||
| Net loss | |||||
| Less: Net loss attributable to non-controlling interests | |||||
| Net loss attributable to the Company’s stockholders’ equity | |||||
| Loss per share from continuing operations (basic) (Note 21) | |||||
| Loss per share from discontinued operations (basic) | |||||
| Total loss per share (basic) | |||||
| Weighted average number of shares of Common Stock outstanding - basic (Note 21) | |||||
| Loss per share from continuing operations (diluted) | |||||
| Loss per share from discontinued operations (diluted) | |||||
| Total loss per share (diluted) | |||||
| Weighted average number of shares of Common Stock outstanding – diluted | |||||
| Other comprehensive loss - Foreign currency translation adjustments | |||||
| Comprehensive income (loss) | |||||
| Other comprehensive income (loss) attributable to non-controlling interests | |||||
| Comprehensive loss attributable to the Company’s stockholders | |||||
Loading...